FDA-Inspected Site

Revance Therapeutics, Inc.

3 FDA inspections are on record for Revance Therapeutics, Inc. in Newark, United States.

483· Form 483 issued

Newark, United States · Last updated July 11, 2026

Overview

  • 3 FDA inspections are on record.
  • 3 inspections produced a Form 483.
  • The most recent recorded inspection date is 2025-02-27.

At a glance

Inspections

3

Form 483s

3

EIRs

2

Last outcome

Form 483

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
19 Feb 2025 – 27 Feb 2025Human Drugs483View 483 →
11 Jul 2022 – 15 Jul 2022Human Drugs483On file
21 Jun 2021 – 2 Jul 2021Human Drugs483On file

Observations on record

Form 483 observations cited at this site, most recent first.

27 Feb 2025
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Linda Thai, Philip F Istafanos

Investigators

FDA investigators tied to this site in the record.

Linda Thai1 insp.
Sarah A Johnson1 insp.
Joao A Pedras Vasconcel1 insp.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind Revance Therapeutics, Inc.'s 3 Form 483s

Source PDFs and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat